OrbiMed’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,964,770
| Closed | -$108K | – | 155 |
|
|
2022
Q2 | $108K | Hold |
1,964,770
| – | – | 1.96% | 16 |
|
|
2022
Q1 | $63M | Buy |
1,964,770
+487,450
| +33% | +$14M | 1.02% | 34 |
|
|
2021
Q4 | $32.1M | Hold |
1,477,320
| – | – | 0.41% | 65 |
|
|
2021
Q3 | $32.4M | Hold |
1,477,320
| – | – | 0.36% | 73 |
|
|
2021
Q2 | $28.8M | Hold |
1,477,320
| – | – | 0.29% | 80 |
|
|
2021
Q1 | $25.5M | Hold |
1,477,320
| – | – | 0.24% | 87 |
|
|
2020
Q4 | $23.7M | Hold |
1,477,320
| – | – | 0.21% | 93 |
|
|
2020
Q3 | $15.8M | Hold |
1,477,320
| – | – | 0.2% | 97 |
|
|
2020
Q2 | $17.9M | Hold |
1,477,320
| – | – | 0.25% | 81 |
|
|
2020
Q1 | $14.5M | Buy |
+1,477,320
| New | +$19.4M | 0.24% | 78 |
|
|
2019
Q2 | – | Sell |
-7,928
| Closed | -$542K | – | 142 |
|
|
2019
Q1 | $542K | Sell |
7,928
-2,500
| -24% | -$160K | 0.01% | 121 |
|
|
2018
Q4 | $551K | Sell |
10,428
-8,750
| -46% | -$559K | 0.01% | 126 |
|
|
2018
Q3 | $1.3M | Sell |
19,178
-12,500
| -39% | -$1.13M | 0.02% | 144 |
|
|
2018
Q2 | $3.75M | Sell |
31,678
-23,415
| -43% | -$2.35M | 0.04% | 132 |
|
|
2018
Q1 | $4.56M | Sell |
55,093
-25,000
| -31% | -$2.83M | 0.06% | 120 |
|
|
2017
Q4 | $11.9M | Sell |
80,093
-12,500
| -13% | -$1.2M | 0.15% | 100 |
|
|
2017
Q3 | $5.74M | Hold |
92,593
| – | – | 0.05% | 120 |
|
|
2017
Q2 | $4.33M | Hold |
92,593
| – | – | 0.05% | 119 |
|
|
2017
Q1 | $5.67M | Buy |
+92,593
| New | +$5.38M | 0.06% | 113 |
|
|
2016
Q2 | – | Sell |
-40,579
| Closed | -$10.9M | – | 147 |
|
|
2016
Q1 | $10.9M | Sell |
40,579
-9,170
| -18% | -$2.93M | 0.12% | 91 |
|
|
2015
Q4 | $29.9M | Hold |
49,749
| – | – | 0.27% | 65 |
|
|
2015
Q3 | $40.8M | Buy |
+49,749
| New | +$56.1M | 0.41% | 49 |
|
Other funds holding SRRA
OrbiMed's SRRA Position: Q3 2022 in Review
OrbiMed sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,964,770 shares — an estimated $108K sold.
OrbiMed first reported a position in SRRA in Q3 2015 and held it in 22 quarters. The position peaked at $63M in Q1 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- OrbiMed reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- OrbiMed sold 1,964,770 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $108K.
- OrbiMed first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 22 quarters.
- OrbiMed's Sierra Oncology, Inc. Common Stock position peaked at $63M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.